Skip to content

News Releases

Date Title and Summary Additional Formats
Toggle Summary Mirati Presents Preliminary Biomarker Data From Ongoing Phase 2 Clinical Trial Of Sitravatinib In Combination With Nivolumab At The SITC 33rd Annual Meeting
SAN DIEGO , Nov. 9, 2018 /PRNewswire/ --  Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, announced preliminary biomarker data from the ongoing Phase 2 clinical trial of sitravatinib in combination with nivolumab (OPDIVO ® ) in non-small cell lung cancer
View HTML
Toggle Summary Mirati Presents Data From Ongoing Phase 2 Clinical Trial Of Mocetinostat In Combination With Durvalumab At The SITC 33rd Annual Meeting
SAN DIEGO , Nov. 9, 2018 /PRNewswire/ --  Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, announced data from the ongoing Phase 2 clinical trial of mocetinostat in combination with durvalumab (IMFINZI ® ) in non-small cell lung cancer (NSCLC) patients at the
View HTML
Toggle Summary Mirati Therapeutics Announces First Patient Dosed In Phase 1b Clinical Trial Of Sitravatinib In Combination With Anti-PD1 Antibody Tislelizumab In Patients With Advanced Solid Tumors
SAN DIEGO , Nov. 8, 2018 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced dosing of the first patient under its collaboration agreement with BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160) in a Phase 1b clinical trial to assess the
View HTML
Toggle Summary Mirati Therapeutics To Present At The 27th Annual Credit Suisse Healthcare Conference
SAN DIEGO , Nov. 7, 2018 /PRNewswire/ --  Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, will present at the 27th Annual Credit Suisse Healthcare Conference in Scottsdale, Arizona on Wednesday, November 14 th at 1:40 p.m. MST / 12:40 p.m. PST . Charles M.
View HTML
Toggle Summary Mirati Therapeutics Reports Third Quarter Financial Results
SAN DIEGO , Nov. 6, 2018 /PRNewswire/ --  Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results for the third quarter ended September 30, 2018 . "We are pleased that our sitravatinib and MRTX849 (KRAS) programs are advancing into the
View HTML
Toggle Summary Mirati To Present New Data In Ongoing Phase 2 Clinical Trials At The SITC 33rd Annual Meeting
- Preliminary biomarker data from the ongoing Phase 2 clinical trial of sitravatinib and nivolumab in NSCLC patients will be presented in an oral presentation - Updated data from the ongoing Phase 2 clinical trial of mocetinostat and durvalumab in NSCLC patients will be presented in an oral
View HTML
Toggle Summary Mirati Therapeutics Announces Submission of IND Application for MRTX849, a KRAS G12C Inhibitor, to Treat Non-Small Cell Lung Cancer and Colorectal Cancer
SAN DIEGO , Oct. 30, 2018 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, announced today that it has submitted an Investigational New Drug (IND) application with the U.S. Food and Drug Administration ( FDA ) to initiate a Phase 1/2 trial with
View HTML
Toggle Summary Mirati Therapeutics Presents Updated Positive Clinical Data From Sitravatinib Immuno-Oncology Combination Trial At ESMO 2018 Congress And Announces FDA Guidance For Registration Trial
- Updated analysis from ongoing Phase 2 trial of sitravatinib in combination with nivolumab demonstrated significant clinical activity in patients with checkpoint refractory non-small cell lung cancer (NSCLC) - 16 partial or complete responses observed in first 56 evaluable patients - Tumor
View HTML
Toggle Summary Mirati Therapeutics Announces Updated Data From Ongoing Clinical Trial Of Single Agent Sitravatinib At The 2018 ESMO Congress
- Clinical data in non-small cell lung cancer (NSCLC) and melanoma patients with CBL inactivating mutations treated with single agent sitravatinib demonstrate encouraging results SAN DIEGO , Oct. 21, 2018 /PRNewswire/ --  Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology
View HTML
Toggle Summary Mirati Therapeutics To Provide Updated Sitravatinib Clinical Data At The European Society For Medical Oncology (ESMO) 2018 Congress And Conduct Investor Call
- Two oral presentations will feature updated clinical data from an ongoing phase 2 clinical trial of sitravatinib in combination with nivolumab and a Phase 1b clinical trial of sitravatinib as a single agent - Proffered Paper Sessions (oral presentations) will include additional clinical trial
View HTML